Biogen (BIIB) closed at $253.40 on November 11, 2026, up 0.1% from the previous close, on volume of 1,072,217 shares (30-day average 1,225,932).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | Calendar Put Spread | 06-Nov : 18-Dec-26 250 P | 2,090 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Mon, 9-Nov 8:10 AM ET)
Biogen Reports Stronger SLE Responses With Investigational Dapirolizumab
TipRanks (Mon, 9-Nov 2:40 AM ET)
Globe Newswire (Mon, 9-Nov 1:00 AM ET)
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Business Wire (Tue, 3-Nov 8:00 AM ET)
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
Business Wire (Thu, 29-Oct 4:01 PM ET)
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Globe Newswire (Thu, 29-Oct 6:59 AM ET)
Business Wire (Thu, 22-Oct 8:00 AM ET)
Globe Newswire (Mon, 19-Oct 7:30 AM ET)
Business Wire (Mon, 5-Oct 7:00 AM ET)
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Biogen trades on the NASDAQ stock market under the symbol BIIB.
As of November 11, 2026, BIIB stock price climbed to $253.40 with 1,072,217 million shares trading.
BIIB has a beta of -0.01, meaning it tends to be less sensitive to market movements. BIIB has a correlation of 0.00 to the broad based SPY ETF.
BIIB has a market cap of $37.46 billion. This is considered a Large Cap stock.
Last quarter Biogen reported $3 billion in Revenue and $2.62 earnings per share. This beat revenue expectation by $178 million and exceeded earnings estimates by $.63.
In the last 3 years, BIIB traded as high as $268.30 and as low as $110.04.
The top ETF exchange traded funds that BIIB belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
BIIB has outperformed the market in the last year with a price return of +62.2% while the SPY ETF gained +12.6%. BIIB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +22.3% and +0.3%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
BIIB support price is $246.70 and resistance is $259.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIIB shares will trade within this expected range on the day.
